procollagen
Ill propeptide #{149} liver disease #{149} diagnostic accuracy Acute viral hepatitis C (VI-IC) is usually an asymptomatic infection, but the long-term consequences may be serious, with progression to chronic hepatitis in most cases and to liver cirrhosis and hepatocellular carcinoma in some. 3 In one study, up to 20% of patients with chronic VHC developed cirrhosis within 5 years [1] .
The prognosis of chronic \THC is closely related to the development of liver fibrosis, which commonly occurs, as in other chronic liver diseases, as the disease progresses. The liver parenchyma is first replaced by connective tissue, then becomes fibrotic, and finally is cirrhotic. This process needs to be assessed in monitoring the course of chronic VHC. At present, the assessment of liver fibrosis necessitates histopathological examination of percutaneous biopsy specimens. This method is both invasive and of questionable value because of the heterogeneous distribution of pathological changes in the liver. As a result, noninvasive biochemical markers for assessing liver fibrosis in chronic hepatitis are being actively sought to help evaluate histological damage and monitor the progression of fibrosis [2] . Liver fibrosis is a complex process involving production and deposition of insoluble components that constitute the extnacellular matrix (ECM). These components can be divided into collagens (types I and HI being predominant in the liven, with lesser amounts of types IV, V, and VI), noncollagenous glycoproteins ( (1-13-4)1 ,j and reaching molecular masses of l0-l0
Da. In the liver, HA is synthesized by the Ito cells and degraded by the sinusoidal endothelial cells [4, 5] . P-Ill-P is the N-terminal cleavage product of procollagen ifi into collagen III, which is synthesized during liver fibrogenesis by Ito cells [6, 7] .
Investigators have found that serum HA concentrations increase in chronic liver diseases; these studies suggest that progressive liver damage can be identified early and managed by serum HA assessment [8] [9] [10] . Like HA, serum P-ffl-P concentrations increase in patients with liver fibrosis [11] [12] [13] , and P-HI-P has mainly been used to study fibrosing conditions of the liver. Several P-Ill-P assays have been developed, varying in their specificities for the intact aminopropeptide and the smaller peptide fragments [14, 15] [16] .
Serum P-HI-P decreases in patients with chronic VHC treated with alpha-interferon, which has an antifibrotic effect [17, 18] , whereas serum HA changes in parallel with liver fibrosis [19] .
Because most patients with VHC develop chronic hepatitis and some of them develop cirrhosis, we decided to include serum HA and P-Ill-P measurements in biological assessment of the disease, using commercially available methods previously used and documented in chronic VHC [17] [18] [19] [20] . To assess and compare the diagnostic accuracy of these two tests as biochemical markers of liver fibrosis or liver cirrhosis in chronic VHC, we carried out receiver-operating characteristic (ROC) analysis of data from a large cohort of 326 untreated patients.
Patients and Methods

PATIENTS
Included
in this study with their informed consent were 326 patients with chronic VHC (178 men and 148 women, mean ± SD ages 43.6 ± 13.5 years) while they were in hospital for clinical, histological, and biological evaluation before potential a-interferon therapy.
All the patients had persistently high serum alanine aminotransferase (more than twice the upper limit of normal values) for at least 6 months and three determinations, had anti-hepatitis C virus (HCV) antibodies (positive by 2nd-generation ELISA), were positive for HCV RNA by polymerase chain reaction, and had liver histological findings consistent with chronic VHC. Among them, 53 had histological evidence of liver cirrhosis. None had been previously treated for VHC, and none had clinical, biological, or histological evidence of other chronic liver disease or pulmonary fibrosis or rheumatic disorders.
Patients with evidence of hepatitis B virus (HBV) infection (detectable serum hepatitis B surface antigen or HBV-DNA) were excluded from the study.
Blood samples were collected between 0800 and 1000 after an overnight fast. Serum was separated without delay and used for routine liver tests or stored at -20 #{176}C until assayed for HA and P-Ill-P.
PROCEDURES
Liver function tests. Total serum bilirubin, alanine aminotransferase activity, aspartate aminotransferase activity, y-glutamyltransfenase activity, alkaline phosphatase activity, and prothrombin time were assayed in all the patients. Biochemical tests were performed with a Synchron CX-4 analyzer (Beckman, Brea, CA), with Soci#{233}t#{233} Fran#{231}aise de Biologie Clinique-recommended procedures for enzyme activities (performed at 30 #{176}C).
Serum hA and serum P-Ill-P measurements.
Serum HA was assessed with a sequential radiometnic assay (HA-test; Pharmacia Diagnostics, Uppsala, Sweden) based on the use of specific HA-binding proteins isolated from bovine cartilage. Intra-and interassay CVs were <7% and <9%, respectively.
The serum reference interval, determined in the laboratory from 30 healthy subjects, was 27 ± 29 jig/L (mean ± SD).
Serum P-Ill-P was assessed with an IRMA using monoclonal antibodies (RIA-gnost P-Ill-P coated tube; Behning). Intra-and interassay CVs were <5% and <7%, respectively.
The serum reference interval, determined in the laboratory from 30 healthy subjects, was 0.41 ± 0.11 kU/L (mean ± SD). To assess and compare the diagnostic accuracy of serum HA and serum P-Ill-P for discriminating in chronic VHC patients those with extensive liver fibrosis from those with no or mild fibrosis or for discriminating those with liver cirrhosis from those without cirrhosis, we plotted ROC curves [22] and calculated the areas under the curves (AUC) for comparison. ROC curves were generated by plotting the relationship of the true positivity (sensitivity) and the false positivity (1 -specificity) at various cutoff points of the tests. 
Results
CHARACTERISTICS OF THE PATIENTS
Liver biochemical and histological tests are given in Table 1 .
Serum HA and serum P-Ill-P concentrations in liver fibrosis. The serum HA and P-Ill-P concentrations according to the fibrosis score are summarized in Table  2 . There were significant differences between the groups of patients. Both HA and P-HI-P concentrations were correlated with the Knodell scores, mainly because they were correlated with the grade of liver fibrosis ( Table 3) .
The patients with extensive liver fibrosis (histological grade of fibrosis = 3 or 4, n = 110) had significantly higher HA or P-ffi-P serum concentrations than the patients with no or mild liver fibrosis (histological grade of fibrosis 0 or 1, n = 216):
HA = 165 ± 62 gfL vs 43 ± 21 tg/L (P <0.001); P-Ill-P = 1.01 ± 0.16 kUIL vs 0.77 ± 0.21 kU/L (P <0.001).
Patients with cirrhosis (n = 53) had significantly higher HA Table 1 . Characteristics of the patients (n = 326). Diagnostic performances. As shown by the ROC curves, in cases of chronic VHC, the ability of serum HA to differentiate patients with extensive liver fibrosis from those with no or mild liver fibrosis exceeded that of serum P-Ill-P (AUC = 0.864 vs 0.691, P <0.0001) (Fig. 1) . The ability to differentiate patients with cirrhosis from those without cirrhosis was also greater for serum HA than for serum P-Ill-P (AUC = 0.924 vs 0.734, P <0.0001) (Fig. 2) . The selected cutoff values for diagnosing extensive liver fibrosis in patients with chronic VHC were 85 pgfL and 0.80 kU/L for serum HA and P-III-P, respectively. The selected cutoff values for diagnosing cirrhosis in patients with chronic VHC were 110 tgfL and 1.00 kU/L for serum HA and P-III-P, respectively. The sensitivity and specificity of each test are shown in Table 4 for the diagnosis of extensive liver fibrosis and for the diagnosis of cirrhosis.
Discussion
Chronic VHC is a progressive disease. Because the prognosis for patients with this disease depends largely on the development of liver fibrosis, leading to cirrhosis, liver damage has to be regularly evaluated. However, histological examination, the "gold standard" for assessing liver lesions, requires liver biopsy, which is potentially associated with severe complications [24, 25] and for ethical reasons cannot be repeated to monitor liver status. Furthermore, this method is not totally reliable because of the high degree of sampling variability [26] .
As a consequence of the difficulties linked to liver histological examination, serum markers of fibrosis are now used in therapeutic trials with patients with chronic VHC [27] . The results of these trials are particularly useful for comparing markers so that investigators can choose an assay suitable for routine patient monitoring.
In the present study, we evaluated and compared the clinical performances of serum P-Ill-P and HA as markers of fibrosis in a large cohort of untreated patients. We found that both serum P-Ill-P and serum HA concentrations are increased in patients with liver fibrosis, the highest concentrations being seen in patients with cirrhosis.
The increase of serum concentrations of these analytes in patients with chronic VHC may reflect the stimulated production of ECM components by activated fat-storing cells, the decreased uptake and degradation by endothelial cells, or both.
The ability of Ito cells to synthesize and secrete collagens and HA has been documented, and Kupffer cells may be involved in stimulating their production through secretion of various mediators [5] . Nevertheless, because blood HA and P-Ill-P are cleared and degraded by liver endothelial cells [28, 29] , serum concentrations might be related to pathological mechanisms that affect sinusoidal cell function and impair plasma uptake.
The serum concentrations of the two studied markers are correlated with the Knodell histological score. Among the different scoring indices of the Knodell score, fibrosis explains this relationship.
The correlations between the P-Ill-P and HA Includes score of fibrosis and score of inflammation and necrosis.
b Includes score of periportal and bridging necrosis (piecemeal necrosis), score of lobular degeneration and focal necrosis, and score of portal inflammation.
serum concentrations and the histologically assessed grade of liver fibrosis were strong, whereas those between the P-Ill-P and HA serum concentrations and the histopathological index of liver inflammation and necrosis were poor. These data, obtained from a large number of subjects, support previous results that showed increases in these two markers of fibrosis in patients with active chronic VHC and a positive correlation of the concentrations of the analytes with the histological scores of fibrosis [12, 13, 27, 30] . They also provide evidence that serum concentrations of HA are more strongly correlated with liver fibrosis than are serum P-Ill-P concentrations. To compare the performance of the two tests, we used ROC plots, which provide pure indices of accuracy [22] . As shown by the relative positions of the plots in Figs. 1 and 2 , the HA assay exhibits greater observed accuracy than does the P-Ill-P assay for diagnosis of extensive fibrosis and for diagnosis of cirrhosis. At any given sensitivity value, the HA value has higher specificity than the P-Ill-P value. Statistical comparison of the AUC shows that the accuracy differehces are highly significant (P <0.0001). The ROC plot AUC is the most convenient global way to quantify the diagnostic accUracy of a test [23] . The AUC values for HA mean that a randomly selected patient with extensive liver fibrosis will have a higher concentration of serum HA than will a randomly selected patient with no or mild fibrosis in 86.4% of the cases; similarly, a randomly selected patient with cirrhosis will have a concentration of serum HA greater than that in randomly selected patients without cirrhosis in 92.4% of the cases. In fact, the evaluation of the diagnostic accuracy of the serum markers of liver fibrosis is limited primarily by the sampling variability of liver biopsy, given that we used histological examination of one sample as the reference value in this study.
Using ROC curve analysis to assess the diagnostic accuracy of a biological marker for use in patient management requires the selection of a decision threshold. The large number of subjects included in this study allowed us to calculate with precision the best cutoff values of serum P-Ill-P and HA for However, the risks and benefits of diagnostic and therapeutic choices made from the results of the assays can be used if it becomes desirable to reoptimize the cutoff values so as to minimize false-positive or false-negative classifications. The differences in diagnostic accuracy of these two serum markers of liver fibrosis found in this study may be related to the fact that serum P-Ill-P concentrations reflect more fibrogenesis and inflammation than fibrosis, as suggested by previous studies [27, 30] , and that serum HA depends primarily on morphological changes that accompany hepatic sinusoidal capillarization in the evolution of chronic diseases to cirrhosis [3 1-33] . Another possible reason for the less-powerful accuracy of serum P-Ill-P is the lack of specificity of the Behring assay for the intact P-ffl-P.
A specific assay [15] should be evaluated in further studies to assess whether using an assay that does not cross-react with degradation products might be more interesting as a marker of liver fibrosis than the assay used here. However, this explanation is not supported by data in alcoholic liver diseases [14] .
In conclusion, in comparison with the results of histological examination, this study shows that serum HA is more accurate than serum P-Ill-P for evaluating liver fibrosis in patients with chronic VHC. This suggests that assay of serum HA may be preferable to assay of P-Ill-P as a noninvasive test for monitoring fibrotic processes in the course of chronic VHC.
